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Identity 
Other names: HSXIAPAF1; BIRC4BP 
Location: 17p13.2 
Local order:  Telomeric to TP53 gene (17p13.1). 
Note: XAF1 not approved by the HUGO Gene 
Nomenclature Committee (HGNC). 
DNA/RNA 
Description 
The XAF1 gene exists as a single copy in the human 
genome; it contains 8 exons and was predicted to span
over approximately 18 kb of the genomic DNA. 
 
Schematic diagram of the XAF1 gene comprising 8 exons (in grey) and transcript variants. The sizes in base pairs (bp) of exons (above) 
and introns (below) are shown. (*) indicates the positions of the stop codons. 
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Transcription 
Five isoforms of XAF1 cDNA have been identified and 
are expressed in a cell and tissue type specific-manner:  
- The original XAF1, also called XAF1(A) (CDS: 
906nt),  
- The XAF1(B) isoform (CDS: 849nt); lacks exon 3,  
- The XAF1(C) isoform (CDS: 495nt); contains exon 
4b and a new stop codon,  
- The XAF1(D) isoform (CDS: 426nt); lacks exons 4b 
and 5 (new stop codon in exon 6),  
- The XAF1(E) isoform (CDS: 369nt); lacks exons 3, 
4b and 5 (new stop codon in exon 6).  
With Northern blot analysis, at least four distinct 
transcripts sizes have been identified in Homo sapiens 
(3.9 kb, 4.5 kb, 6.0 kb and 7.0 kb). How these mRNA 





The full length XAF1 protein consists of 301 amino 
acids corresponding to a molecular weight of 33.411 
kDa. The protein contains seven zinc fingers domains. 
The XAF1(B) isoform is predicted to lack the third N-
terminal zinc finger of the previously described XAF1. 
The XAF1(C) is predicted to contain the first five 
amino-terminal zinc finger domains of the previously 
described XAF1 and also a unique 24 aa carboxy 
terminus. There is no evidence for XAF1 isoforms (C), 
(D) and (E) expression at the protein level. 
Expression 
Normal tissue: ubiquitous and differential expression in 
normal tissues; highest in heart and ovary and lowest in 
brain and testis at mRNA levels. The XAF1 protein 
also displays differential protein expression profile 
within normal cell or tissue development including 
placenta and motoneurons. 
Cancer: as opposed to normal cells, XAF1 is found 
either low or undetectable in tumor cell lines at bo h 
mRNA and protein levels. Expression varies also 
widely among different tumor cell lines. High levels of 
XAF1 protein were found in glioblastoma cells (SF-
539) and ovarian cells (OVCAR-5). Detectable levels 
were found also in various gastric and colon cancer cell 
lines and also myeloma cells (U266). 
Localisation 
Nuclear and cytoplasmic distribution. 
Function 
Tumor suppressor gene: loss of heterozygosity (LOH) 
found in 12 of 33 (36%) human primary colorectal 
carcinomas. The absence or reduced expression of 
XAF1 in cancer cell lines by genetic or epigenetic  
modifications have suggested a possible role in the 
suppression of development and/or progression of 
malignancy. 
IAP antagonist: XAF1 exerts a proapoptotic effect by 
directly interacting with BIRC4/XIAP and 
antagonizing its anticaspase activity. XAF1 enhances 
XIAP E3 ligase activity towards BIRC5/Survivin 
through a complex and mediates Survivin down-
regulation. 
Interferon (IFN)-stimulated gene (ISG): XAF1 is an 
important mediator of IFN-induced sensitization to 
TNF-related apoptosis-inducing ligand (TRAIL) in 
cancer. 
Increasing expression of XAF1 sensitizes cells to 
apoptosis-induced by various stimuli including 
etoposide, 5-FU, TRAIL, anti-Fas Ab, TNFalpha, UV, 
H2O2, gamma-irradiation. 
Homology 
XAF1 shares high amino acid similarity with the zinc 
finger domains of FLN29 and TRAF6. 
Mutations 




No somatic mutations in tumor cell lines examined. 
LOH described in colon tumors. 
Epigenetics 
Aberrant promoter hypermethylation in the 5' proximal 
region (from +3nt to -234 nt) in a variety of gastric, 
colon, bladder, kidney and prostate cancer cell lines 
and tumors. 
Implicated in 
Colorectal cancer, gastric cancer, 
urogenital cancer 
Oncogenesis 
XAF1 is proposed to be a tumor suppressor gene. 
Correlation of reduction in XAF1 expression with stage 
and grade within gastric and colorectal tumors 
demonstrating that the loss of XAF1 contributes to 
tumorigenesis. 
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